Targets › ERCC2
2 programs from 2 companies in 12 trials: 9 Phase 4, 2 Phase 2, 1 Phase 1; Cardiovascular, Immunology, Infectious disease; next expected readout Dec 2027.
ATP-dependent 5'-3' DNA helicase. Component of the general transcription and DNA repair factor IIH (TFIIH) core complex, not absolutely essential for minimal transcription in vitro. (UniProt, P18074)
Open in Phaseline: the race on ERCC2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bausch Health Americas | Clindamycin Bacterial 70S ribosome inhibitor | ERCC1, ERCC2 | Phase 4 | Acne Vulgaris; Skin Infection; Infection Control / Methods; Surgical Site Infection … | Dec 2027 |
| M.D. Anderson Cancer Center | Trabectedin Alkylating agent - binds DNA and inhibits transcription, particularly affecting transcript | ERCC2, ERCC3 | Phase 2 | Uterine Leiomyosarcoma; Soft Tissue Sarcomas | Dec 2027 |
Acne Vulgaris (2) Skin Infection (1) Infection Control / Methods (1) Surgical Site Infection (1) Endocarditis Infective (1) Wisdom Tooth Removal (1) Cat Bite (1) Staphylococcus Aureus Bacteremia (1) Aortic Surgery (1) Uterine Leiomyosarcoma (1) Soft Tissue Sarcomas (1)
small molecule (1), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.